Surgical Approaches for Spondylolisthesis
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment for spondylolisthesis?
Research shows that patients with degenerative spondylolisthesis who had decompression and fusion surgery had better outcomes than those with decompression alone. Additionally, a study on high-grade L5-S1 spondylolisthesis found positive results with reduction and fusion using a single posterior approach.12345
Is surgery for spondylolisthesis generally safe?
Surgical techniques like paraspinal muscle sparing and percutaneous screw fixation are considered safer than traditional methods, as they reduce muscle injury and complications. These minimally invasive approaches often lead to shorter hospital stays, quicker recovery, and less post-operative pain.678910
How does the surgical approach for spondylolisthesis differ from other treatments?
The surgical approach for spondylolisthesis, which includes spinal fusion and decompressive laminectomy, is unique because it combines techniques to relieve pressure on the spinal cord and stabilize the spine. This approach can be less invasive, reducing muscle trauma and recovery time compared to traditional methods, and may involve advanced techniques like 3D navigation to minimize radiation exposure.49101112
What is the purpose of this trial?
For the increasing numbers of patients undergoing fusion procedures for the degenerative lumbar spine, infection and re-operation can negatively impact outcomes. Numerous observational and retrospective reviews have shown advantages to para-median versus midline approaches; however, recent systematic reviews have shown a need for a well-powered, prospective randomized control trials comparing both exposures. As a step towards a long-term goal of an RCT to address this issue, the purpose of this pilot study is to gather initial data to examine whether operative approach impacts the short-term infection rate, re-operation rate, length of stay, and overall costs to the system. Patients deemed appropriate surgical candidates with single or two-level degenerative spondylolisthesis will be approached for participation, and randomized into either the midline or paramedian group. Initial follow-ups will be at 2 and 6 weeks, and 3 months. Infection rates, inpatient and outpatient adverse events, re-operation rates, radiation exposure and costs will be determined. Cost effectiveness analysis will be estimated comparing each procedure using a bottom-up estimation. Post-operative wound infection can have a significant effect on patient short and long term outcomes. If a significant difference in infection rate is demonstrated, as well as lower re-operation rates, shorter stays, and decreased overall costs, adoption of paramedian approaches to single or two-level fusions of the lumbar spine might be suggested, providing fuel for a full-scale RCT.
Eligibility Criteria
This trial is for patients with degenerative lumbar spondylolisthesis who've had back and leg pain for over 6 months that's better when sitting or bending forward. They should have tried other treatments without success and must speak English well enough to give informed consent and fill out questionnaires.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either a midline or paramedian surgical approach for lumbar fusion
Initial Follow-up
Initial follow-ups to assess post-operative recovery and collect patient-reported outcomes
Extended Follow-up
Further follow-up to monitor infection rates and other outcomes
Long-term Follow-up
Participants are monitored for infection rates and other outcomes over a longer period
Treatment Details
Interventions
- Surgical approach
Surgical approach is already approved in United States, European Union for the following indications:
- Degenerative lumbar spondylolisthesis
- Isthmic spondylolisthesis
- Degenerative lumbar spondylolisthesis
- Isthmic spondylolisthesis
- Degenerative lumbar spondylolisthesis
- Isthmic spondylolisthesis
- Degenerative lumbar spondylolisthesis
- Isthmic spondylolisthesis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Nova Scotia Health Authority
Lead Sponsor
Andrew Glennie
Lead Sponsor